CCND1 and glioblastoma: Naringin treatment of U251 glioblastoma cells and U87 glioblastoma cells restricts their growth by inhibiting the cyclin D1 pathway or FAK pathway and induces the death of cells by inhibiting the BAD pathway or FAK pathway.